Abstract: Currently, immune checkpoint inhibitors (ICPIs) are the most compelling approach in cancer therapy, which expanded theboundary of treatment of cancer to immune-based therapy. Compared to traditional chemotherapy, immunotherapy significantly prolongs survival while conferring fewer side effects. Because of the new mechanism of the ICPIs with good clinical efficacy, they havebeen approved for sale in a short time. However, the mechanism of immune-related adverse events have yet fully understood for astandardized management strategy. With further development of immunotherapy and possible combination therapy, adverse eventsof ICPIs gain more attention. Here, we focuses on the reported adverse events and the treatment experience to provide theoretical basis for their treatment.